-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-4215 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-4215 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-4215 in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Deucravacitinib in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deucravacitinib in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deucravacitinib in Chronic Cutaneous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Hidradenitis Suppurativa Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-6043 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-6043 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-6043 in Prostate Cancer Drug Details: ART-6043 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-6043 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-6043 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-6043 in Solid Tumor Drug Details: ART-6043 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-6043 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-6043 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-6043...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-0380 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-0380 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-0380 in Endometrial Cancer Drug Details: ART-0380 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-0380 in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-0380 in Anal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-0380 in Anal Cancer Drug Details: ART-0380 is under development for the...